Loading...
Chemical structure of Rebastinib

GC14007

Rebastinib

Also listed as DCC-2036 (Rebastinib)

DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0·8 nM and 4 nM, respectively· DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit

ChemicalCAS1020172-07-9MW553.59FormulaC30H28FN7O3
CAS number
1020172-07-9
Molecular weight
553.59
Formula
C30H28FN7O3
Solubility
≥ 27·7mg/mL in DMSO
InChIKey
WVXNSAVVKYZVOE-UHFFFAOYSA-N
Catalogue number
GC14007
Brand
GLPBIO
Computed properties PubChem CID 25066467 · XLogP 4.9 · TPSA 123 Ų · H-bond donors 3
XLogP
4.9
TPSA
123 Ų
H-bond donors
3
H-bond acceptors
7
Rotatable bonds
7
Heavy atoms
41

SMILES CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5

Computed descriptors from PubChem (CID 25066467), public domain. Identity cross-checked against the supplier's molecular formula and weight — verify before use.

Ordering in Israel

Lead time
Ships from the manufacturer to your lab in 8–14 business days; customs and cold chain handled by LABO Scientific.
Pricing
Quoted in ILS, excl. VAT. Add the item to your quote and we confirm the final price, usually the same business day.
Documents
Lot certificate of analysis and manufacturer SDS are emailed with your order confirmation.
Who we serve
Universities, hospitals and biotech companies across Israel. Research use only — not for diagnostic or therapeutic use.